MICS safer and more effective than torsional phaco

Article

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

Panagiotis Zafirakis and colleagues from the Diagnostic and Therapeutic Eye Center, Hellenic Ophthalmochirourgiki, Athens conducted a randomized, comparative study of 120 eyes, which were assigned to phacoemulsification by MICS (60 eyes) or torsional ultrasound (60 eyes) modes. Bimanual phacoemulsification was performed using a quick chop technique.

Mean operating time (5.11 versus 7.30 minutes), effective phaco time (3±5.31 versus 9.37±6.80 seconds) and mean percentage of ultrasound power (6.67±1.66 versus 18.88±2.77) were statistically significantly shorter (p<0.01) with the MICS platform compared with the torsional system. Mean volume of irrigation fluid used (134±11.3 ml versus 175±27.5 ml) and mean endothelial cell loss (3.6% versus 5.3%) were also significantly lower with the MICS system (p<0.001). There were three capsular ruptures in the torsional group and none in the MICS group. Furthermore, there were seven cases of postoperative corneal fold or oedema in the torsional group and only one in the MICS group. Postoperative best-corrected visual acuity (BCVA) was similar in both groups.Overall, it was concluded, the MICS platform is a safer and more effective system than torsional phacoemulsification.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.